Protocol for the OUTREACH trial: a randomised trial comparing delivery of cancer systemic therapy in three different settings - patient's home, GP surgery and hospital day unit-Reference-Cited by-同舟云学术

Protocol for the OUTREACH trial: a randomised trial comparing delivery of cancer systemic therapy in three different settings - patient's home, GP surgery and hospital day unit

Published:2011-10-29 Issue:1 Volume:11 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Corrie Pippa G,Moody Margaret,Wood Victoria,Bavister Linda,Prevost Toby,Parker Richard A,Sabes-Figuera Ramon,McCrone Paul,Balsdon Helen,McKinnon Karen,O'Sullivan Brendan,Tan Ray S,Barclay Stephen IG

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-11-467.pdf

Reference21 articles.

1. Calman K, Hine D: A policy framework for commissioning cancer services. Department of Health London. 1995, 18-

2. Our Health, Our Care, Our Say: a new direction for community services. Department of Health. 2006

3. Gorski LA, Grothman L: Home infusion therapy. Sem Oncol Nursing. 1996, 12: 193-201. 10.1016/S0749-2081(96)80037-4.

4. Watters C: The benefits of providing chemotherapy at home. Professional Nurse. 1997, 12: 367-70.

5. Dougherty L, Viner C, Young J: Establishing ambulatory chemotherapy at home. Professional Nurse. 1998, 13: 356-8.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of chemotherapy treatment administration via venous port and peripheral vascular access in terms of quality of life and costs;Quality of Life Research;2023-02-15

2. État des lieux de l’activité pédiatrique en hospitalisation à domicile (HAD) en France;Perfectionnement en Pédiatrie;2019-06

3. Chimiothérapie intraveineuse à domicile en cancérologie pédiatrique : une expérience monocentrique;Bulletin du Cancer;2018-02

4. A multi-method review of home-based chemotherapy;European Journal of Cancer Care;2015-11-06

5. The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial;PharmacoEconomics;2015-09-04